Viral entry and the resulting inflammation are key mechanisms under investigation by SARS-CoV-2 researchers. We provide SARS-CoV-2 recombinant proteins and antibodies to investigate the interactions between S1 spike protein and human ACE2 for viral entry. Our ELISA kits and LEGENDplex™ assays can further characterize early inflammation and the efficacy of interventions by tracking the cytokine response. By fully understanding the virus’ starting point and its subsequent effects on the body, we can dismantle SARS-CoV-2 before it has a chance to even start.